Breaking News Instant updates and real-time market news.

HD

Home Depot

$191.15

0.82 (0.43%)

, TSLA

Tesla

$291.84

-9.19 (-3.05%)

08:59
05/15/18
05/15
08:59
05/15/18
08:59

On The Fly: Pre-market Movers

HIGHER: Intellia Therapeutics (NTLA), up 7% after the stock was upgraded to Buy from Neutral at Chardan... Symantec (SYMC), up 3% after the company hosted a belated Q&A call and the stock was upgraded to Hold from Underperform at Jefferies... Aerie Pharmaceuticals (AERI), up 10% after submitting its new drug application to the FDA for Roclatan eye drops. UP AFTER EARNINGS: Hollysys (HOLI), up 5%. DOWN AFTER EARNINGS: Home Depot (HD), down 3%... Agilent (A), down 7%... Vipshop (VIPS), down 16.5%... Switch (SWCH), down 10%. ALSO LOWER: Tesla (TSLA), down 3% after Morgan Stanley analyst Adam Jonas made significant cuts to his near-term and long-term auto margin forecasts for Tesla and cut his price target on the stock to $291 from $376.

HD

Home Depot

$191.15

0.82 (0.43%)

TSLA

Tesla

$291.84

-9.19 (-3.05%)

NTLA

Intellia Therapeutics

$24.59

0.87 (3.67%)

SYMC

Symantec

$21.40

1.89 (9.69%)

VIPS

Vipshop

$15.10

-0.01 (-0.07%)

SWCH

Switch

$15.46

0.145 (0.95%)

A

Agilent

$69.24

-0.22 (-0.32%)

HOLI

Hollysys

$22.10

0.25 (1.14%)

AERI

Aerie Pharmaceuticals

$52.40

1.5 (2.95%)

  • 15

    May

  • 15

    May

  • 15

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 30

    May

  • 07

    Jun

HD Home Depot
$191.15

0.82 (0.43%)

05/09/18
CLVD
05/09/18
NO CHANGE
CLVD
Lowe's comp gap versus Home Depot could widen, says Cleveland Research
Cleveland Research said Lowe's (LOW) comp gap versus Home Depot (HD) could widen further given continued disruptions and inefficiencies in execution.
05/09/18
CLVD
05/09/18
NO CHANGE
CLVD
Home Depot 2018 comp estimate of 6% looks reasonable, says Cleveland Research
Cleveland Research said its Home Depot 2018 comp estimate of 6%, versus guidance of 5%, looks reasonable given solid underlying demand, share gains, and incremental inflation.
04/23/18
WELS
04/23/18
INITIATION
Target $205
WELS
Outperform
Home improvement and autopart retail offers favorable pockets, says Wells Fargo
As reported earlier, Wells Fargo analyst Zachary Fadem initiated select names within the home improvement, auto part retail, home furnishings, and specialty hardlines. The analyst notes that the pullback in some of these stocks related to "uncertainty around margins, global trade policy, and the sustainability of recently improving results", which replaced the enthusiasm from the anticipated consumer strength, rising wages, and tax reform benefits earlier this year, has produced some "compelling" long-term investment opportunities. Fadem initiated Home Depot (HD) and Lowe's (LOW) at Outperform with respective price targets of $205 and $100, saying home improvement is particularly attractive in retail today given the valuations in housing and demographics tailwinds. The analyst adds that the home improvement category has seen the most consistent growth in "consumer share of wallet" to 7.5% over the past 5 years, even though that level is still below 8.7% prior peak in 2005. Fadem's view on Bed Bath and Beyond (BBBY) is less upbeat with an Underperform rating and a $16 price target based on its limited growth opportunity, margin profile, differentiation, and e-commerce strategy. Similarly, the analyst profiles the auto parts retail offering some opportunity in terms of "lost share of wallet" sliding to 1.8%, below the 10-year average of 1.9%, while offering "attractive valuations" and an opportunity to regain its footing. Fadem initiates O'Reilly (ORLY) and AutoZone (AZO) with an Outperform rating and price targets of $260 and $700 respectively, adding that these two companies exceeded the industry growth even as auto parts retailers as a group trade at a 23% discount relative to the S&P500. The analyst also initiated select names in the Home Furnishings/Specialty categories, including At Home (HOME) at Outperform with a price target of $42, Tractor Supply (TSCO) at Outperform with a price target of $70, and National Vision (EYE) with an Outperform and a price target of $40. Fadem. All of these names earned a positive view based on the analysts Growth Opportunity and Concept Differentiation screens, with the last two also cited for their potential for near term improvement.
05/15/18
BARD
05/15/18
NO CHANGE
Target $215
BARD
Outperform
Home Depot weakness a buying opportunity, says Baird
Baird analyst Peter Benedict said softer seasonal sales impacted by weather was the reason for Home Depot's revenue miss in Q1. He said the company is seeing strong momentum thus far in May and 2018 guidance was maintained, so he would be a buyer of any weakness following the quarterly report. Benedict reiterated his Outperform rating and $215 price target on Home Depot shares, which are down about 2.7% to $186 in early pre-market trading.
TSLA Tesla
$291.84

-9.19 (-3.05%)

05/03/18
GSCO
05/03/18
NO CHANGE
Target $195
GSCO
Sell
Tesla cash levels lower than anticipated, says Goldman Sachs
Goldman Sachs analyst David Tamberrino kept his Sell rating and $195 price target on Tesla after its "mixed" Q1 earnings, saying that while gross margins were better than expected, the company's cash levels were below his forecasts. The analyst also cites "sparse" details around the improvement for Tesla's Fremont manufacturing facility and points to the company's rising net debt levels.
05/03/18
BARD
05/03/18
NO CHANGE
Target $411
BARD
Outperform
Tesla weakness a buying opportunity, says Baird
Baird analyst Ben Kallo said Tesla's Q1 results beat on all metrics and recommend investors ignore all the noise about Musk not answering several questions on the conference call. He said investors should focus on the company's progress and recommended buying the shares. The analyst said demand remains strong, the company lowered its capex estimates, and the company continues to execute on its strategy. Kallo reiterated his Outperform rating and $411 price target on Tesla shares.
05/15/18
MSCO
05/15/18
NO CHANGE
Target $291
MSCO
Equal Weight
Tesla price target lowered to $291 from $376 at Morgan Stanley
Morgan Stanley analyst Adam Jonas made significant cuts to his near-term and long-term auto margin forecasts for Tesla following the company's Q1 report to reflect lingering manufacturing issues with the Model 3, which drove his price target on the stock down to $291 from $376. He has also delayed his forecast for the launch of Tesla's mobility-as-a-service network by roughly a year, to the middle of 2019, and increased his estimate for Tesla's capital raising to $3B from $2.5B. Jonas, who continues to expect Tesla will raise capital in the third quarter of this year, believes an added level of caution is prudent regarding Tesla and maintains an Equal Weight rating on the shares.
05/11/18
NOMU
05/11/18
NO CHANGE
Target $420
NOMU
Buy
Nomura lays out path to Tesla hitting $500 per share in two years
Nomura Instinet analyst Romit Shah believes the narrative on Tesla will shift over the next six months from insolvency risk and cash burn to market opportunity and growth. The analyst created a "Tesla Storyboard," which lays out the path to a $100B valuation, or $500 stock price, within two years. He keeps a Buy rating on Tesla with a $420 price target.
NTLA Intellia Therapeutics
$24.59

0.87 (3.67%)

03/07/18
LEHM
03/07/18
NO CHANGE
Target $46
LEHM
Overweight
Intellia Therapeutics price target raised to $46 from $33 at Barclays
Barclays analyst Gena Wang raised her price target for Intellia Therapeutics (NTLA) to $46 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Intellia shares and keeps an Overweight rating on the name.
05/15/18
CHDN
05/15/18
UPGRADE
CHDN
Buy
Intellia Therapeutics upgraded to Buy from Neutral at Chardan
01/09/18
JEFF
01/09/18
NO CHANGE
Target $42
JEFF
Buy
Intellia selloff yesterday a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft views yesterday's selloff in shares of Intellia Therapeutics as a buying opportunity. The analyst calls the pullback "excessive" based on his analysis of Friday's publication related to CRISPR/Cas9 that raised safety/efficacy questions pertaining to the genome-editing technology. The analyst views the data in the publication as early and limited. He keeps a Buy rating on Intellia with a $42 price target.
03/08/18
JMPS
03/08/18
INITIATION
Target $76
JMPS
Outperform
Intellia Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Michael King started Intellia Therapeutics with an Outperform rating and $76 price target, stating that the company is leading competitors in the gene-editing space in its efforts to develop in vivo gene-editing approaches and that its partnerships validate its in vivo LNP approach.
SYMC Symantec
$21.40

1.89 (9.69%)

05/15/18
DBAB
05/15/18
NO CHANGE
Target $22
DBAB
Hold
Symantec call lessened near-term risk, says Deutsche Bank
The belated Q&A call hosted by Symantec, where management said they are not expecting a material adverse impact on the company's financials from the audit investigation, lessened the near-term risk, Deutsche Bank analyst Karl Keirstead tells investors in a research note. The analyst believes, however, that the audit probe risk will linger. Nonetheless, he concludes that the debate will now pivot to the likelihood of Symantec hitting "what looks like aggressive" fiscal 2020 targets. Keirstead keeps a Hold rating on the shares with a $22 price target.
05/11/18
MSCO
05/11/18
NO CHANGE
Target $26
MSCO
Equal Weight
Morgan Stanley says Symantec 'too hot to handle' given investigation uncertainty
After Symantec's FY19 guidance came in well below consensus expectations and "perhaps more concerning" the company announced an unspecified audit committee investigation, Morgan Stanley analyst Keith Weiss called the stock "too hot to handle" given that the matter was said to preclude the management team from taking any questions from analysts, either publicly or privately. Weiss, who thinks the investigation will likely remain an open question for some time, lowered his price target on the stock to $26 from $31 and keeps an Equal Weight rating on Symantec shares.
05/11/18
05/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kohl's (KSS) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Binetti saying he sees first quarter same store sales risk due to cold weather damaging industry traffic and Kohl's being more weather sensitive than its peers, and slightly lowered his Q1 EPS estimate on the stock. 2. Symantec (SYMC) downgraded to Sell from Neutral at MoffettNathanson, to Equal Weight from Overweight at Barclays and First Analysis, to Perform from Outperform at Oppenheimer, and to Neutral from Buy at BTIG, to Neutral from Outperform at Macquarie, and to Neutral from Overweight at Piper Jaffray. 3. AMC Networks (AMCX) downgraded to In Line on valuation at Evercore ISI with analyst David Joyce citing valuation. 4. L Brands (LB) downgraded to Neutral from Overweight at Atlantic Equities. 5. Presidio (PSDO) downgraded to Sector Perform from Outperform at RBC Capital and to Market Perform from Outperform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/18
JEFF
05/15/18
UPGRADE
Target $22
JEFF
Hold
Symantec upgraded to Hold from Underperform at Jefferies
Jefferies analyst John DiFucci upgraded Symantec to Hold and raised his price target for the shares to $22 from $20. While difficult, if not impossible, to assess the outcome of the current investigation, there's a base value for the business that is not far from the current price, DiFucci tells investors in a research note. He points out, however, that it "remains unclear whether the company will return to growth."
VIPS Vipshop
$15.10

-0.01 (-0.07%)

02/13/18
02/13/18
UPGRADE
Target $20

Outperform
Follow-up: Vipshop upgraded to Outperform on growth prospects at Macquarie
As previously reported, Macquarie upgraded Vipshop to Outperform from Neutral following the Q4 beat and better than expected Q1 guidance. Analyst Wendy Huang raised Vipshop's price target to $20 from $9 and increased estimates due to stronger growth prospects Huang believes the tie-ups with Tencent and JD.com will drive accelerated user acquisitions, generate synergies in the logistics business, and enable Vipshop to attract more brands and better SKUs.
02/14/18
BNCH
02/14/18
NO CHANGE
Target $24
BNCH
Buy
Vipshop price target raised to $24 on 'milestone' partnership at Benchmark
Benchmark analyst Fawne Jiang raised her price target on Vipshop (VIPS) to $24 from $12, stating that its partnership with Tencent (TCEHY) and JD.com (JD) is a "milestone" step with both substantial financial benefits and the potential to unleash Vipshop's strategic value as an e-commerce asset. Jiang reiterated her Buy rating on Vipshop shares following the company's "solid" Q4 report.
02/13/18
02/13/18
UPGRADE
Target $20

Outperform
Vipshop upgraded to Outperform on improved growth prospects at Macquarie
As previously reported, Macquarie analyst Wendy Huang upgraded Vipshop (VIPS) to Outperform from Neutral following the company's revenue and earnings beat in Q4. Huang believes the company's recently announced tie-up with Tencent (TCEHY) and JD.com (JD) has strengthened its growth prospects, as it can accelerate user acquisitions and help the company attract more brands and better products to sell. Huang, who also reiterated JD.com as her top pick among e-commerce names, has a $20 price target on Vipshop shares.
02/13/18
MACQ
02/13/18
UPGRADE
MACQ
Outperform
Vipshop upgraded to Outperform from Neutral at Macquarie
SWCH Switch
$15.46

0.145 (0.95%)

05/11/18
COWN
05/11/18
UPGRADE
Target $14.5
COWN
Market Perform
Switch upgraded to Market Perform at Cowen
As reported previously, Cowen analyst Colby Synesael upgraded Switch to Market Perform from Underperform. The analyst cited a new 15MW lease and a $100M increase in incremental contract value. He also believes share could remain range bound given the potential for insider sales and its relatively low returns. Synesael has a $14.50 price target on Switch shares.
04/03/18
BMOC
04/03/18
NO CHANGE
Target $20
BMOC
Outperform
Switch price target lowered to $20 from $23 at BMO Capital
BMO Capital analyst Tim Long lowered his price target on Switch to $20 to reflect the lowered data center REIT peer multiples and his updated model with FY19 EBITDA estimates. The analyst keeps his Outperform rating on Switch following its Q4 earnings beat however, forecasting "strong organic growth" as the company expands its campuses and leverages key partnerships. Longer term, Long expects Switch to benefit from the secular cloud transition in tech, and believes colocation will be one of the fastest growing components of this trend.
03/12/18
RAJA
03/12/18
UPGRADE
RAJA
Outperform
Switch upgraded to Outperform from Market Perform at Raymond James
05/10/18
COWN
05/10/18
UPGRADE
COWN
Market Perform
Switch upgraded to Market Perform from Underperform at Cowen
A Agilent
$69.24

-0.22 (-0.32%)

04/09/18
GSCO
04/09/18
UPGRADE
Target $77
GSCO
Buy
Goldman upgrades Agilent to Buy ahead of Q1 earnings season
Goldman Sachs analyst Patrick Donnelly upgraded Agilent Technologies (A) to Buy from Neutral and raised his price target for the shares to $77 from $73. Heading into the Q1 earnings season, the analyst sees an attractive fundamental backdrop across Tools. He believes, however, that the favorable backdrop is well understood by investors with valuations that "remain well-above 10-year highs." The analyst prefers the "idiosyncratic drivers of growth" for Agilent in the out years and views the stock's relative valuation as attractive. He coupled the upgrade with a downgrade of Mettler-Toledo (MTD) to Neutral.
04/09/18
04/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he sees room for positive earnings revisions for GM, Ford (F) and Fiat Chrysler (FCAU) as investors better understand the impact on U.S. pick-up truck sales from a potential passage of a U.S. infrastructure bill. 2. TD Ameritrade (AMTD) upgraded to Buy from Neutral at BofA/Merrill with analyst Michael Carrier saying he views TD Ameritrade's near-term outlook as attractive given healthy new net asset growth, higher interest rates, and strong DARTs. 3. Comerica (CMA) upgraded to Outperform from Neutral at Wedbush with analyst Peter Winter saying he sees several levers that should drive above average earnings per share growth over the next two years, including margin expansion, potential resumption of loan growth, and above average capital returns. 4. Agilent (A) upgraded to Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools. 5. Discover (DFS) and Ally Financial (ALLY) were upgraded to Equal Weight from Underweight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/18
BARD
05/15/18
NO CHANGE
Target $77
BARD
Outperform
Agilent core growth slowing, but underlying business healthy, says Baird
Baird analyst Catherine Ramsey Schulte said Agilent's Q2 growth hit the guidance midpoint, but fell short of expectations due to unforeseen headwinds in China and ICP/MS shipment timing. She noted management remains bullish on end-market outlooks and she still believes they are being conservative with guidance. Although the company's core growth is slowing, she said the underlying business is healthy. Schulte reiterated her Outperform rating and lowered her price target to $77 from $78 on Agilent shares.
05/15/18
JEFF
05/15/18
NO CHANGE
Target $80
JEFF
Buy
Agilent pullback a buying opportunity, says Jefferies
Jefferies analyst Brandon Couillard recommends using the post-earnings pullback in shares of Agilent Technologies as a buying opportunity. Guidance was maintained, despite dilution from Lasergen, and does not yet capture accretion from the pending AATI deal, Couillard tells investors in a research note. He sees no reason to alter his positive thesis and keeps a Buy rating on Agilent with a slightly reduced price target of $80.
HOLI Hollysys
$22.10

0.25 (1.14%)

05/15/18
SBSH
05/15/18
UPGRADE
SBSH
Buy
Hollysys upgraded to Buy from Neutral at Citi
Citi upgraded Hollysys Automation Technologies to Buy following last night's Q3 results and raised its price target for the shares to $26.30 from $25.90. The firm highlights the company's faster expansion into automation.
05/15/18
JPMS
05/15/18
UPGRADE
JPMS
Overweight
Hollysys upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Karen Li upgraded Hollysys Automation Technologies to Overweight citing an acceleration of industrial automation order growth and its expanding factory automation business. Citi this morning also upgraded Hollysys following the company's Q3 results.
09/28/17
DBAB
09/28/17
NO CHANGE
Target $25
DBAB
Buy
Hollysys target raised to $25 after management meetings at Deutsche Bank
After hosting non-deal roadshows with management, Deutsche Bank analyst Sky Hong raised Hollysys Automation Technologies' price target to $25 from $23. The shares, despite rebounding 25% from lows over the past three months, still do not reflect the company's "multi-year robust growth," Hong tells investors in a research note partially titled "another leg of re-rating looks well-deserved." The analyst keeps a Buy rating on Hollysys.
02/09/18
JPMS
02/09/18
DOWNGRADE
JPMS
Neutral
Hollysys downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Karen Li downgraded Hollysys Automation Technologies to Neutral following the company's Q2 results.
AERI Aerie Pharmaceuticals
$52.40

1.5 (2.95%)

01/26/18
GHSC
01/26/18
INITIATION
Target $78
GHSC
Buy
Aerie Pharmaceuticals initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Aerie Pharmaceuticals with a Buy and $78 price target. The analyst expects a successful Q2 launch for Rhopressa in glaucoma, a market that has not seen a new chemical entity in more than 20 years. Davis believes this novel mechanism that targets the site of disease pathology to drive usage in combination therapy for those patients that are not reaching goal with their current glaucoma treatments. This corrects a prior note regarding the reasons for the analyst's rating.
02/16/18
HCWC
02/16/18
INITIATION
Target $78
HCWC
Buy
Aerie Pharmaceuticals assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat assumed coverage of Aerie Pharmaceuticals with a Buy rating and $78 price target.
03/01/18
CANT
03/01/18
NO CHANGE
Target $86
CANT
Overweight
Aerie Pharmaceuticals price target raised to $86 from $77 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aerie Pharmaceuticals to $86 to reflect the decrease in the future tax rate to 21% from 35%. The analyst reiterates an Overweight rating on the shares following the company's Q4 results.
05/01/18
MZHO
05/01/18
NO CHANGE
Target $77
MZHO
Buy
Aerie Pharmaceuticals price target lowered to $77 from $87 at Mizuho
Mizuho analyst Difei Yang lowered her price target for Aerie Pharmaceuticals to $77 citing a reduction in takeover premium in her valuation. The analyst does not expect a takeover to occur during the Rhopressa launch phase. Yang keeps a Buy rating on Aerie and continues to have confidence that management can successfully execute the launch.

TODAY'S FREE FLY STORIES

PM

Philip Morris

$80.34

-1.27 (-1.56%)

04:55
05/28/18
05/28
04:55
05/28/18
04:55
Conference/Events
Philip Morris management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

03:05
05/28/18
05/28
03:05
05/28/18
03:05
General news
FX Update: The euro has firmed »

FX Update: The euro has…

KORS

Michael Kors

$68.63

0.25 (0.37%)

, LULU

Lululemon

$106.18

-0.19 (-0.18%)

11:07
05/26/18
05/26
11:07
05/26/18
11:07
Periodicals
Dollar Tree looks interesting, Barron's says »

Next week, another 20…

KORS

Michael Kors

$68.63

0.25 (0.37%)

LULU

Lululemon

$106.18

-0.19 (-0.18%)

GME

GameStop

$12.64

-0.1 (-0.78%)

DLTR

Dollar Tree

$95.23

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 12

    Jun

  • 14

    Jun

  • 26

    Jun

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

, QCOM

Qualcomm

$59.95

0.85 (1.44%)

10:58
05/26/18
05/26
10:58
05/26/18
10:58
Periodicals
Kraft Heinz, J&J among safe, 'solid' dividend stocks, Barron's says »

Kraft Heinz (KHC),…

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

QCOM

Qualcomm

$59.95

0.85 (1.44%)

MRK

Merck

$59.08

-0.03 (-0.05%)

TGT

Target

$71.22

0.28 (0.39%)

OMC

Omnicom

$71.98

-0.1 (-0.14%)

CCL

Carnival

$64.27

0.12 (0.19%)

JNJ

Johnson & Johnson

$121.40

0.06 (0.05%)

MMM

3M

$198.98

-0.38 (-0.19%)

LLY

Eli Lilly

$82.75

0.05 (0.06%)

VLO

Valero

$118.81

-3.06 (-2.51%)

EMR

Emerson

$72.50

-0.77 (-1.05%)

WBA

Walgreens Boots Alliance

$63.52

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 02

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 19

    Jun

  • 10

    Sep

  • 23

    Oct

MU

Micron

$61.33

-0.15 (-0.24%)

10:48
05/26/18
05/26
10:48
05/26/18
10:48
Periodicals
Micron can solve low valuation, Barron's says »

Micron's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ATUS

Altice USA

$18.50

-0.05 (-0.27%)

10:40
05/26/18
05/26
10:40
05/26/18
10:40
Periodicals
Altice's spinoff could be winning bet, Barron's says »

On June 8, Altice will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

MU

Micron

$61.33

-0.15 (-0.24%)

, XLNX

Xilinx

$69.63

0.88 (1.28%)

10:35
05/26/18
05/26
10:35
05/26/18
10:35
Periodicals
AI revolution just getting started, Barron's says »

Artificial Intelligence…

MU

Micron

$61.33

-0.15 (-0.24%)

XLNX

Xilinx

$69.63

0.88 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:08
05/26/18
05/26
08:08
05/26/18
08:08
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

HMC

Honda

$32.04

-0.34 (-1.05%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$11.51

-0.11 (-0.95%)

GM

General Motors

$38.30

-0.09 (-0.23%)

TM

Toyota

$129.97

-2.47 (-1.87%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAC

Bank of America

$30.16

-0.03 (-0.10%)

C

Citi

$68.42

-0.86 (-1.24%)

GS

Goldman Sachs

$235.05

-1.1 (-0.47%)

JPM

JPMorgan

$110.62

-0.64 (-0.58%)

MS

Morgan Stanley

$53.02

-0.96 (-1.78%)

USB

U.S. Bancorp

$50.54

-0.14 (-0.28%)

WFC

Wells Fargo

$54.91

0.25 (0.46%)

TWTR

Twitter

$33.64

0.11 (0.33%)

AA

Alcoa

$47.92

-1.26 (-2.56%)

CENX

Century Aluminum

$16.27

-0.07 (-0.43%)

AOBC

American Outdoor Brands

$12.53

0.05 (0.40%)

RGR

Sturm, Ruger

$63.10

0.5 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

  • 22

    Jun

  • 13

    Jul

  • 27

    Jul

  • 10

    Sep

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 15

    Jul

  • 15

    Oct

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.